PRME

Prime Medicine Stock Analysis

AI Rating

Low
  • Quality0/10
  • Growth↑ 5/10
  • Value↓ 0/10
Prime Medicine sales and earnings growth
PRME Growth
Neutral
  • Revenue Y/Y↓ 4.89%
  • EPS Y/Y↑ 22.36%
  • FCF Y/Y↓ -42.49%
Prime Medicine gross and profit margin trends
PRME Profitability
Low
  • Gross margin ↑ 100.00%
  • EPS margin↓ -4917.60%
  • ROIC 5Y↓ -100.11%
Prime Medicine net debt vs free cash flow
PRME Risk
Good
  • Debt / Equity↓ 1.5
  • Debt / FCF↓ 0.2
  • Interest coverage↓ NA

Prime Medicine stock volatility is higher than the overall market. We give it a Good risk rating.

↗ More Biotechnology stocks